1. Home
  2. COE vs CTMX Comparison

COE vs CTMX Comparison

Compare COE & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

COE

51Talk Online Education Group

HOLD

Current Price

$32.96

Market Cap

246.1M

Sector

Real Estate

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.08

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COE
CTMX
Founded
2011
2008
Country
Singapore
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
246.1M
596.2M
IPO Year
2016
2015

Fundamental Metrics

Financial Performance
Metric
COE
CTMX
Price
$32.96
$4.08
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$6.50
AVG Volume (30 Days)
24.6K
2.9M
Earning Date
12-08-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.22
EPS
N/A
0.24
Revenue
$81,215,000.00
$113,631,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$17.49
Revenue Growth
93.72
N/A
52 Week Low
$13.60
$0.40
52 Week High
$56.13
$4.62

Technical Indicators

Market Signals
Indicator
COE
CTMX
Relative Strength Index (RSI) 36.47 51.05
Support Level $32.03 $3.86
Resistance Level $33.92 $4.48
Average True Range (ATR) 1.57 0.26
MACD 0.03 -0.00
Stochastic Oscillator 24.63 43.57

Price Performance

Historical Comparison
COE
CTMX

About COE 51Talk Online Education Group

51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in seven principal geographical area: China, Hong Kong, Philippines, Singapore, Malaysia, Thailand and Saudi Arabia.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: